Tag - pfizer

 
 

PFIZER

Japan Times
ASIA PACIFIC
Jan 16, 2023
In China, no easy way to get Pfizer's COVID drug Paxlovid
Beijing has acknowledged that supplies are still insufficient to meet demand, even as millions of courses of the treatment were shipped to the country recently.
Japan Times
WORLD / Science & Health
Jan 14, 2023
Pfizer's bivalent vaccine linked to rare strokes in older people in preliminary U.S. data
The early finding still needs more investigation, and recommendations for the vaccine have not been changed, a statement by the U.S. Food and Drug Administration said.
Japan Times
ASIA PACIFIC / Science & Health
Jan 7, 2023
China in talks with Pfizer for generic COVID drug
Beijing is in talks with the drugmaker to secure a license that will allow domestic firms to manufacture and distribute a generic version of its Paxlovid antiviral drug.
Japan Times
COMMENTARY / World
Nov 21, 2022
Pfizer’s RSV vaccine succeeds where others failed
Early data bodes well for Pfizeru2019s RSV shot, which would be given during pregnancy to protect infants in the early months of life.
Japan Times
WORLD / Science & Health
Nov 7, 2022
Pfizer’s Paxlovid anti-viral seen to lower long-COVID risk in study
Taking the oral medication within five days of testing positive for a SARS-CoV-2 infection was linked to a 26% lower risk of lingering post-viral complications, researchers found.
Japan Times
WORLD / Science & Health
Nov 5, 2022
Study shows new booster improves protection for older people, Pfizer says
U.S. officials are hoping that the encouraging results will improve what has so far been a dismal public response to the retooled shots.
Japan Times
JAPAN
Sep 12, 2022
Japan health ministry backs Pfizer and Moderna omicron boosters
Pfizeru2019s omicron booster can be administered to people age 12 and over, while Modernau2019s is limited to those 18 and above, the panel advised.
Japan Times
JAPAN / Science & Health / EXPLAINER
Aug 12, 2022
What we know about the new omicron vaccines
New vaccines developed for the COVID-19 omicron variant are scheduled to be available from mid-October in Japan, raising hopes that the population will soon be better protected.
Japan Times
JAPAN
Aug 10, 2022
Shionogi confirms efficacy of oral COVID drug for omicron subvariant
The announcement came after a health ministry panel in July postponed the granting of emergency approval for the drug.
Japan Times
BUSINESS / Companies
Aug 9, 2022
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
Pfizer will gain Oxbryta, South San Francisco-based Global Bloodu2019s therapy for sickle-cell disease that sold about $195 million last year.
Japan Times
COMMENTARY / World
Apr 11, 2022
We need better COVID-19 booster shots, not more of the same
There are 100 new Covid vaccines in development. One of them could offer better protection against omicron.
Japan Times
ASIA PACIFIC / Science & Health
Apr 4, 2022
China promotes traditional cures as Pfizer pill alternatives
China is struggling to persuade skeptics to put aside doubts about traditional medicine that hasnu2019t gone through large, standardized clinical trials.
Japan Times
WORLD / Science & Health
Mar 27, 2022
Second vaccine booster significantly lowers COVID-19 death rate: Israeli study
Senior citizens who received a second booster of the Pfizer-BioNTech COVID-19 vaccination had a 78% lower mortality rate from the disease than those who got one only.
Japan Times
BUSINESS
Mar 15, 2022
Drugmakers pause trials in Russia while still sending medicine
Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russiau2019s invasion of Ukraine and the needs of sick patients.
Japan Times
JAPAN / Science & Health
Feb 16, 2022
Despite ministry recommendation, some parents in Japan wary of COVID jabs for children
Vaccinations for children ages 5 to 11 could start by the end of February, with the government recommending all children receive a shot, particularly those with underlying conditions.
Japan Times
ASIA PACIFIC
Feb 15, 2022
China’s approval of Pfizer pill opens door to ending 'COVID zero'
Having an effective anti-viral in its arsenal could help China mitigate the lower efficacy of its homegrown vaccines if the virus was allowed to circulate more freely.
Japan Times
JAPAN / Science & Health
Feb 10, 2022
Japanese health ministry approves Pfizer's COVID-19 oral treatment drug
The drug, paxlovid, is to be used for the treatment of mild-to-moderate COVID-19 in people 12 and older and who are at high risk of developing severe symptoms.
Japan Times
JAPAN
Feb 7, 2022
Japan's booster rollout is relying on Pfizer and Moderna. How do the shots compare?
Despite an apparent preference among some in the general public for Pfizer, experts have emphasized that getting a booster jab as soon as one is eligible, no matter which type, is key.
Japan Times
WORLD / Science & Health
Feb 1, 2022
How does Merck's COVID-19 pill compare to Pfizer's?
Pfizer said final trial results showed that its treatment reduced the chance of hospitalization or death by 89%, while Merck said their pill reduced those chances by 30%.
Japan Times
WORLD
Jan 26, 2022
Pfizer and BioNTech launch trial of omicron-targeted COVID-19 vaccine
The companies plan to test the immune response generated by the omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot.

Longform

Hideo Shimoju points to a possible site that his fellow neighbors may relocate to. Such relocations have happened before, but not preemptively.
In disaster-prone Japan, some communities consider major moves